Overa (ASPiRA Labs)February 1, 2018
At present, the overall estimated 5-year survival rate for ovarian cancer is 46.5%. Early identification does impact prognosis; however, the majority of ovarian cancer patients are diagnosed with advanced-stage disease, where survival rates are low. Biomarker analysis for risk stratification assessments for ovarian cancer, specifically adnexal masses, aims to increase early diagnosis and subsequent benefit from early intervention.
If you have a Hayes login, click here to view the full report on the Knowledge Center.